A macromolecule infliximab loaded reverse nanomicelles-based transdermal hydrogel: An innovative approach against rheumatoid arthritis
Source abstract
Abstract
Infliximab (IFX) is used as a biotherapeutic agent for the treatment of rheumatoid arthritis (RA); however, its biological activity is lost orally because of variations in gastric pH and enzymatic degradation, and reduced bioavailability. The authors have tried to improve the efficacy of macromolecule delivery through transdermal route. Polycaprolactone-Polyethylene glycol-Polycaprolactone (PCL-PEG-PCL) triblock copolymer previously synthesized and was used as an efficient carrier for the preparation of IFX loaded reverse nanomicelles (IFX-RNMs). The RNMs were fabricated via nanoprecipitation technique, characterized and then were incorporated into a Carbopol-based hydrogel with eucalyptus oil (EO) as a penetration enhancer. The optimized RNMs had a particle size of 72.32 nm and an encapsulation efficiency of 83 %. In vitro release, exhibited a sustained pattern of IFX from the prepared carrier system, ex-vivo skin permeation and fluorescence microscopic studies revealed that IFX-RNMs loaded hydrogel with EO markedly improved permeation. An in vivo study was carried out on a CFA-induced RA mice model that revealed significant improvements in the results of behavioral parameters, biochemical assays, histopathological and radiological analysis. Overall, the results concluded that the IFX-RNMs loaded hydrogel can be used as a suitable approach for treating RA.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Pharmacological Effects of Natural Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (67)
Show source-provided references
1. Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy10.1016/j.jconrel.2020.09.016 ↗
2. Recent trends in stimuli-responsive hydrogels for the management of rheumatoid arthritis
3. The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis10.1007/s10067-019-04900-y ↗
4. Anti-rheumatoid drugs advancements: new insights into the molecular treatment of rheumatoid arthritis
5. Nanoengineered therapy aiming at the etiology of rheumatoid arthritis10.1016/j.nantod.2021.101367 ↗
6. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2013–201510.15585/mmwr.mm6609e1 ↗
7. Utility of a novel inflammatory marker
8. A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritis
9. F. Yuan, L.-d. Quan, L. Cui, S.R. Goldring, D. Wang, Development of macromolecular prodrug for rheumatoid arthritis, Adv. Drug Deliv. Rev. 64 (2012) 1205–19.10.1016/j.addr.2012.03.006 ↗
10. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy10.7150/thno.47601 ↗
11. Infliximab-based self-healing hydrogel composite scaffold enhances stem cell survival, engraftment, and function in rheumatoid arthritis treatment10.1016/j.actbio.2020.12.005 ↗
12. Microneedle-mediated transdermal delivery of bevacizumab10.1021/acs.molpharmaceut.8b00544 ↗
13. Influence of molecular weight on transdermal delivery of model macromolecules using hydrogel-forming microneedles: potential to enhance the administration of novel low molecular weight biotherapeutics10.1039/D0TB00021C ↗
14. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: from conventional to cutting edge in biologics and RNA-based nanomedicines
15. Tundisi · 2022 · 113043
16. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model10.1186/s12951-020-00693-4 ↗
17. Site-selective oral delivery of therapeutic antibodies to the inflamed colon via a folic acid-grafted organic/inorganic hybrid nanocomposite system10.1016/j.apsb.2022.06.006 ↗
18. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease10.1016/j.cej.2022.136438 ↗
19. Dendritic nanotheranostic for the delivery of infliximab: a potential carrier in rheumatoid arthritis therapy10.3390/ijms21239101 ↗
20. Perspectives on the past, present, and future of cancer nanomedicine10.1016/j.addr.2018.05.008 ↗
21. Nanomedicines for the treatment of rheumatoid arthritis: state of art and potential therapeutic strategies10.1016/j.apsb.2021.03.013 ↗
22. Molecular Architecture
23. Block copolymer micelles in nanomedicine applications10.1021/acs.chemrev.8b00199 ↗
24. Nanomedicine–advantages for their use in rheumatoid arthritis theranostics10.1016/j.jconrel.2019.11.008 ↗
25. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity10.1038/s41392-021-00830-x ↗
26. Permeation enhancer strategies in transdermal drug delivery10.3109/10717544.2014.935532 ↗
27. Essential oils and their constituents as skin penetration enhancer for transdermal drug delivery: a review10.1111/jphp.12334 ↗
28. A reverse micelle strategy for fabricating magnetic lipase-immobilized nanoparticles with robust enzymatic activity10.1038/s41598-017-10453-4 ↗
29. Surfactant-free, self-assembled nanomicelles-based transdermal hydrogel for safe and targeted delivery of methotrexate against rheumatoid arthritis10.1021/acsnano.0c00364 ↗
30. Nanocrytals-mediated oral drug delivery: enhanced bioavailability of amiodarone10.3390/pharmaceutics14061300 ↗
31. Ur Rehman, pH-responsive mupirocin-loaded hybrid nanoparticles in hydrogel and film forming spray against resistant bacterial wound infections
32. Development of novel pH-sensitive nanoparticles loaded hydrogel for transdermal drug delivery10.1080/03639045.2019.1569031 ↗
33. Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats10.1080/10717544.2017.1413447 ↗
34. Topical nano-emulgel for skin disorders: formulation approach and characterization10.2174/1574891X14666181129115213 ↗
35. Stability testing of new drug substances and products, Q1A (R2)
36. Development of an intelligent, stimuli-responsive transdermal system for efficient delivery of ibuprofen against rheumatoid arthritis10.1016/j.ijpharm.2021.121242 ↗
37. The kinetics of the amidase and esterase activities of trypsin10.1016/S0021-9258(19)51261-3 ↗
38. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase10.1016/S0021-9258(19)50881-X ↗
39. Mechanisms of solute release from porous hydrophilic polymers10.1016/0378-5173(83)90064-9 ↗
40. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices10.1002/jps.2600521210 ↗
41. Dependence of reaction velocity upon surface and agitation10.1021/ie50260a018 ↗
42. Transdermal delivery of indirubin-loaded microemulsion gel: preparation, characterization and anti-psoriatic activity10.3390/ijms23073798 ↗
43. Enhancement in site-specific delivery of carvacrol for potential treatment of infected wounds using infection responsive nanoparticles loaded into dissolving microneedles: A proof of concept study10.1016/j.ejpb.2019.12.008 ↗
44. Chitosan-chondroitin based artemether loaded nanoparticles for transdermal drug delivery system10.1016/j.jddst.2020.102281 ↗
45. Lipase-sensitive fusidic acid polymeric nanoparticles based hydrogel for on-demand delivery against MRSA-infected burn wounds10.1016/j.jddst.2022.104110 ↗
46. Fabrication of bergenin nanoparticles based hydrogel against infected wounds: an in vitro and in vivo study10.1016/j.jddst.2023.104364 ↗
47. Fangchinoline has an anti-arthritic effect in two animal models and in IL-1β-stimulated human FLS cells10.4062/biomolther.2020.113 ↗
48. Development of novel pH-sensitive nanoparticle-based transdermal patch for management of rheumatoid arthritis10.2217/nnm-2019-0385 ↗
49. Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia10.1016/j.neuropharm.2017.07.029 ↗
50. Metals-triggered compound CDPDP exhibits anti-arthritic behavior by downregulating the inflammatory cytokines, and modulating the oxidative storm in mice models with extensive ADMET, docking and simulation studies
51. Dewan · 2016
52. Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice10.1136/ard.2010.132720 ↗
53. 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, MD simulations, in vitro and in vivo studies to identify potential anti-hyperplasia drugs10.1002/biot.202300437 ↗
54. Immunostimulant, hepatoprotective, and nephroprotective potential of Bacillus subtilis (NMCC-path-14) in comparison to dexamethasone in alleviating CFA-induced arthritis
55. Development and in vitro/in vivo evaluation of pH-sensitive polymeric nanoparticles loaded hydrogel for the management of psoriasis10.3390/nano11123433 ↗
56. Nano anti-tumor necrosis factor-alpha based potentiometric sensor for tumor necrosis factor-alpha detection10.1016/j.snb.2014.12.063 ↗
57. FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies10.1016/j.aca.2020.03.038 ↗
58. 3D printed infliximab suppositories for rectal biologic delivery
59. In vivo imaging of activated macrophages by 18F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs)10.1016/j.bbrc.2018.10.083 ↗
60. Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation, drug delivery and translational
61. Stability of infliximab solutions in different temperature and dilution conditions10.1016/j.jpba.2017.12.012 ↗
62. Intraarticular injection of infliximab-loaded thermosensitive hydrogel alleviates pain and protects cartilage in rheumatoid arthritis, journal of pain
63. Nitric oxide production of T lymphocytes is increased in rheumatoid arthritis10.1016/j.imlet.2008.02.009 ↗
64. An ameliorated anti-hTNF-α therapy for arthritis via carrier-free macromolecular nanoparticles consisted of infliximab10.1016/j.ijpharm.2022.122414 ↗
65. Multifunctional Janus Nanoplatform for efficiently synergistic Theranostics of rheumatoid arthritis10.1021/acsnano.2c11777 ↗
66. Biomimetic hybrid membrane-coated xuetongsu assisted with laser irradiation for efficient rheumatoid arthritis therapy10.1021/acsnano.1c07556 ↗
67. Novel polyurethane-based nanoparticles of infliximab to reduce inflammation in an in-vitro intestinal epithelial barrier model10.1016/j.ijpharm.2019.05.025 ↗